Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q5032274> ?p ?o }
Showing triples 1 to 29 of
29
with 100 triples per page.
- Q5032274 subject Q7204516.
- Q5032274 subject Q8431759.
- Q5032274 subject Q8616356.
- Q5032274 subject Q8878163.
- Q5032274 subject Q8919936.
- Q5032274 subject Q8955377.
- Q5032274 abstract "Canertinib (CI-1033) is an experimental drug candidate for the treatment of cancer. It is an irreversible tyrosine-kinase inhibitor with activity against EGFR (IC50 0.8 nM), HER-2 (IC50 19 nM) and ErbB-4 (IC50 7 nM).Drug Interactions: Canertinib has been reported as a substrate for OATP1B3. Interaction of canertinib with OATP1B3 may alter its hepatic disposition and can lead to transporter mediated drug-drug interactions. Also, canertinib is not an inhibitor of OATP-1B1 or OATP-1B3 transporter.".
- Q5032274 iupacName "N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide".
- Q5032274 thumbnail Canertinib.svg?width=300.
- Q5032274 wikiPageWikiLink Q14865565.
- Q5032274 wikiPageWikiLink Q14877486.
- Q5032274 wikiPageWikiLink Q17917202.
- Q5032274 wikiPageWikiLink Q427492.
- Q5032274 wikiPageWikiLink Q7204516.
- Q5032274 wikiPageWikiLink Q8431759.
- Q5032274 wikiPageWikiLink Q8616356.
- Q5032274 wikiPageWikiLink Q8878163.
- Q5032274 wikiPageWikiLink Q8919936.
- Q5032274 wikiPageWikiLink Q8955377.
- Q5032274 wikiPageWikiLink Q906415.
- Q5032274 iupacname "N-{4-[amino]-7-[3-propoxy]quinazolin-6-yl}prop-2-enamide".
- Q5032274 type ChemicalCompound.
- Q5032274 type ChemicalSubstance.
- Q5032274 type ChemicalObject.
- Q5032274 type Thing.
- Q5032274 type Q11173.
- Q5032274 comment "Canertinib (CI-1033) is an experimental drug candidate for the treatment of cancer. It is an irreversible tyrosine-kinase inhibitor with activity against EGFR (IC50 0.8 nM), HER-2 (IC50 19 nM) and ErbB-4 (IC50 7 nM).Drug Interactions: Canertinib has been reported as a substrate for OATP1B3. Interaction of canertinib with OATP1B3 may alter its hepatic disposition and can lead to transporter mediated drug-drug interactions. Also, canertinib is not an inhibitor of OATP-1B1 or OATP-1B3 transporter.".
- Q5032274 label "Canertinib".
- Q5032274 depiction Canertinib.svg.